Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Apr 29:rs.3.rs-4314795.
doi: 10.21203/rs.3.rs-4314795/v1.

Frailty trajectories preceding dementia: an individual-level analysis of four cohort studies in the United States and United Kingdom

Affiliations

Frailty trajectories preceding dementia: an individual-level analysis of four cohort studies in the United States and United Kingdom

David Ward et al. Res Sq. .

Update in

  • Frailty Trajectories Preceding Dementia in the US and UK.
    Ward DD, Flint JP, Littlejohns TJ, Foote IF, Canevelli M, Wallace LMK, Gordon EH, Llewellyn DJ, Ranson JM, Hubbard RE, Rockwood K, Stolz E. Ward DD, et al. JAMA Neurol. 2025 Jan 1;82(1):61-71. doi: 10.1001/jamaneurol.2024.3774. JAMA Neurol. 2025. PMID: 39527039 Free PMC article.

Abstract

Frailty may represent a modifiable risk factor for dementia, but the direction of that association remains uncertain. We investigated frailty trajectories in the years preceding dementia onset using data from 23,672 participants (242,760 person-years of follow-up, 2,906 cases of incident dementia) across four cohort studies in the United States and United Kingdom. Bayesian non-linear models revealed accelerations in frailty trajectories 4-9 years before incident dementia. Among participants whose time between frailty measurement and incident dementia exceeded that prodromal period, frailty remained positively associated with dementia risk (adjusted hazard ratios ranged from 1.20 [95% confidence interval, CI = 1.15-1.26] to 1.43 [95% CI = 1.14-1.81]). This observational evidence suggests that frailty increases dementia risk independently of any reverse causality. These findings indicate that frailty measurements can be used to identify high-risk population groups for preferential enrolment into clinical trials for dementia prevention and treatment. Frailty itself may represent a useful upstream target for behavioural and societal approaches to dementia prevention.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement DW, JR, TL, IF, MC, LW, EG, DL, JR, RH and ES have nothing to report. KR reports grants from Nova Scotia Health Research Fund, during the conduct of the study; personal fees from Ardea Outcomes, the Chinese Medical Association, Wake Forest University Medical School Centre, the University of Nebraska - Omaha, the Australia New Zealand Society of Geriatric Medicine, the Atria Institute, Fraser Health Authority, Fraser Health Authority, McMaster University, and EpiPharma Inc, outside the submitted work; In addition, Dr. Rockwood has licensed the Clinical Frailty Scale (CFS) to Enanta Pharmaceuticals, Inc, Synairgen Research Ltd, Faraday Pharmaceuticals, Inc., KCR S.A., Icosavax, Inc, BioAge Labs Inc, Biotest AG, Qu Biologics Inc, AstraZeneca UK Litd, Cellcolabs AB, Pfizer Inc, W.L. Gore Associates Inc, pending to Cook Research Incorporated and Rebibus Therapeutics Inc; has licensed the Pictorial Fit-Frail Scale (PFFS) to Congenica;,and as part of Ardea Outcomes Inc has a pending patent for Electronic Goal Attainment Scaling. Use of both the CFS and PFFS is free for education, research and non-profit health care with completion of a permission agreement stipulating users will not change, charge for or commercialize the scales. For-profit entities (including pharma) pay a licensing fee, 15% of which is retained by the Dalhousie University Office of Commercialization and Innovation Engagement. The remainder of the license fees are donated to the Dalhousie Medical Research Foundation and the QEII Health Sciences Centre Research Foundation. In addition to academic and hospital appointments, KR is co-founder of Ardea Outcomes (DGI Clinical until 2021), which in the past 3 years has had contracts with pharma and device manufacturers (Danone, Hollister, INmune, Novartis, Takeda) on individualized outcome measurement.

Figures

Figure 1
Figure 1. Participant exclusions and analytical samples.
ELSA, English Longitudinal Study of Ageing; HRS, Health and Retirement Study; MAP, Rush Memory and Aging Project; NACC, National Alzheimer’s Coordinating Center.
Figure 2
Figure 2. Frailty trajectories before dementia.
Plots used expected frailty index scores calculated from Bayesian mixed-effects gamma regression models that included fixed effects of time, time x event group, age, sex and education, as well as random participant intercepts and slopes. For the trajectory plots, the thicker lines are mean trajectories surrounded by 95% credible intervals and the thinner lines represent raw (unadjusted) data from 20 participants randomly selected from each group. For the forest plots, mean differences (95% confidence intervals) are between the censored group (reference line) and the incident dementia group, and the dashed line represents the estimated start of the pre-dementia frailty acceleration period. ELSA, English Longitudinal Study of Ageing; HRS, Health and Retirement Study; MAP, Rush Memory and Aging Project; NACC, National Alzheimer’s Coordinating Center.
Figure 3
Figure 3. Associations of frailty and incident dementia.
Hazard ratios were calculated from Cox proportional-hazards models that included covariates of age, sex and education. Sensitivity analysis 1, the pre-dementia frailty acceleration period was increased by two years; sensitivity analysis 2, deficits found to be independently associated with incident dementia were removed from the calculation of frailty index scores. Details regarding sizes of samples and subgroups included in these analyses are presented in Table 3. ELSA, English Longitudinal Study of Ageing, HRS, Health and Retirement Study; MAP, Rush Memory and Aging Project; NACC, National Alzheimer’s Coordinating Center.

References

    1. Boyle P. A. et al. Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies. Ann Neurol 85, 114–124 (2019). - PMC - PubMed
    1. Nichols E. et al. The prevalence, correlation, and co-occurrence of neuropathology in old age: harmonisation of 12 measures across six community-based autopsy studies of dementia. Lancet Healthy Longev 4, e115–e125 (2023). - PMC - PubMed
    1. Hou Y. et al. Ageing as a risk factor for neurodegenerative disease. Nat Rev Neurol 15, 565–581 (2019). - PubMed
    1. Melo Dos Santos L. S., Trombetta-Lima M., Eggen B. & Demaria M. Cellular senescence in brain aging and neurodegeneration. Ageing Res Rev 93, 102141 (2023). - PubMed
    1. Gonzales M. M. et al. Senolytic therapy in mild Alzheimer’s disease: a phase 1 feasibility trial. Nat Med 29, 2481–2488 (2023). - PMC - PubMed

Publication types

Grants and funding

LinkOut - more resources